CLPT
ClearPoint Neuro Inc. Healthcare Medical Devices
8/12
Innovation Score
Patent Activity
3/3
13 patents found
OK_NORMALIZED
Cash Runway
0/3
12 months of cash remaining based on current burn rate.
Cash on hand: $29.4M
Cash on hand: $29.4M
Revenue Trajectory
2/3
Revenue: $42.3M
YoY Growth: +18.1%
YoY Growth: +18.1%
Management Quality
3/3
Insider ownership: 13.8%
SBC/Revenue: 10.4%
No reverse splits detected
SBC/Revenue: 10.4%
No reverse splits detected
Key Metrics
Market Cap
$474.3M
Revenue
$42.3M
Revenue Growth (YoY)
+18.1%
Cash on Hand
$29.4M
Cash Runway
12 months
Shares Outstanding
30.5M
Insider Ownership
13.8%
SBC / Revenue
10.4%
Sector / Industry
Healthcare / Medical Devices
Patents (13)
Match type: OK_NORMALIZED
- Automatic, patient-specific targeting for deep brain stimulation
- Patient-specific infusion coverage estimates using segmented 3D brain representations
- Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
- Extension tube assembly and related medical fluid transfer systems and methods
- Method for bone collision detection using a stereotactic image-guided navigation system
7-Step Risk Assessment
How CLPT maps to our micro cap methodology:
- Innovation Signal 13 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 12 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory +18.1% YoY growth on $42.3M revenue. Positive but moderate growth.
- Management Alignment Insiders hold 13.8% of shares. SBC is 10.4% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $474.3M company.
Financial Detail
Free Cash Flow
$-14.1M
FCF Yield
-3.0%
Return on Equity
-226.5%
Debt / Equity
593.4%
Gross Margin
62.6%
Profit Margin
-81.8%
Operating Margin
-94.2%
Price / Book
44.05
Current Ratio
4.75
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-08-29